Hospital
University of Southern California
University of Southern California was paid $15.43M by Medicaid between Jan 2018 and Aug 2021, across 146 billing codes. Its largest line is J9299, Injection, nivolumab, 1 mg — 22% of everything it billed.
33Billing provider infoUNIVERSITY OF SOUTHERN CALIFORNIA
LOS ANGELES, CA 90089
LOS ANGELES, CA 90089
33aNPI1770728438assigned 12/10/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.43M
24GClaims172,690
24DCodes billed146
24AFirst – last monthJan 2018 – Aug 2021
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#143 of 410
Median peer was paid$6.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,776 | $3.85M | |
| 2019 | 48,725 | $3.73M | |
| 2020 | 43,476 | $7.03M | |
| 2021 | 11,713 | $806K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | 22% | 1,214 | 513 | $3.39M |
| J9271 | Injection, pembrolizumab, 1 mg | 16% | 422 | 270 | $2.47M |
| J0897 | Injection, denosumab, 1 mg | 8.3% | 883 | 767 | $1.28M |
| 80053 | Comprehensive metabolic panel | 5.3% | 17,126 | 11,404 | $819K |
| J2505 | Injection, pegfilgrastim, 6 mg | 3.9% | 85 | 67 | $595K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.2% | 5,901 | 3,550 | $487K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 4,307 | 2,315 | $487K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 743 | 701 | $408K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.4% | 1,519 | 1,435 | $368K |
| 74178 | 2.2% | 606 | 576 | $341K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 2.0% | 309 | 220 | $314K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.0% | 14,257 | 11,604 | $312K |
134 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 16,025 | $281K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 1.8% | 214 | $278K |
| J9035 | Injection, bevacizumab, 10 mg | 1.5% | 206 | $231K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1.3% | 2,763 | $207K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.0% | 5,272 | $160K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,331 | $150K |
| 0510 | <1% | 3,523 | $137K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,387 | $125K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,743 | $117K |
| 83735 | <1% | 6,539 | $117K | |
| 0272 | <1% | 532 | $115K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,108 | $108K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 153 | $106K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 352 | $102K |
| Z7500 | <1% | 2,965 | $101K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,384 | $86K |
| 96417 | <1% | 1,407 | $86K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 96 | $85K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,420 | $75K |
| 96415 | <1% | 1,506 | $72K | |
| 77336 | <1% | 703 | $69K | |
| 0250 | <1% | 3,423 | $69K | |
| 0761 | <1% | 975 | $66K | |
| 99221 | <1% | 2,771 | $59K | |
| 77386 | <1% | 118 | $54K | |
| 77334 | <1% | 116 | $53K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 687 | $52K |
| 80197 | <1% | 2,113 | $47K | |
| 96367 | <1% | 1,041 | $46K | |
| 84100 | <1% | 4,602 | $43K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,125 | $42K |
| 87497 | <1% | 868 | $42K | |
| 83615 | <1% | 6,161 | $41K | |
| 85027 | <1% | 2,481 | $33K | |
| 99199 | Unlisted special service, procedure or report | <1% | 53 | $31K |
| 96411 | <1% | 385 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,425 | $27K |
| 82378 | <1% | 1,630 | $27K | |
| 86850 | <1% | 1,855 | $26K | |
| J3490 | Unclassified drugs | <1% | 690 | $22K |
| 77300 | <1% | 106 | $22K | |
| 82728 | <1% | 1,462 | $21K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 44 | $21K |
| J9312 | Injection, rituximab, 10 mg | <1% | 19 | $20K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,670 | $19K |
| 85610 | <1% | 1,345 | $19K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 141 | $17K |
| A9270 | Non-covered item or service | <1% | 1,599 | $16K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,452 | $16K |
| 96416 | <1% | 127 | $15K | |
| 86901 | <1% | 1,990 | $15K | |
| 86900 | <1% | 1,955 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 687 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 629 | $14K |
| 88321 | <1% | 302 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 541 | $13K |
| 77301 | <1% | 12 | $12K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 99 | $12K |
| 81001 | <1% | 1,308 | $12K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 82 | $12K |
| 82105 | <1% | 541 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 109 | $10K |
| 85730 | <1% | 830 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 420 | $10K |
| J9310 | Injection, rituximab, 100 mg | <1% | 20 | $9K |
| 84153 | <1% | 840 | $9K | |
| 71250 | <1% | 68 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 261 | $9K |
| 86301 | <1% | 549 | $9K | |
| 36592 | <1% | 213 | $8K | |
| 96402 | <1% | 267 | $8K | |
| 86141 | <1% | 756 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 373 | $6K |
| 0710 | <1% | 26 | $6K | |
| 83520 | <1% | 284 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 63 | $5K |
| 77338 | <1% | 13 | $5K | |
| 36430 | <1% | 78 | $4K | |
| 84439 | <1% | 243 | $4K | |
| 86920 | <1% | 82 | $4K | |
| 76642 | <1% | 13 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 79 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 190 | $3K |
| 84550 | <1% | 133 | $3K | |
| 82784 | <1% | 222 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 66 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 333 | $2K |
| 84165 | <1% | 324 | $2K | |
| 0760 | <1% | 134 | $2K | |
| 82565 | <1% | 214 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 283 | $2K |
| A4649 | Surgical supply; miscellaneous | <1% | 215 | $2K |
| 83540 | <1% | 352 | $2K | |
| 86300 | <1% | 158 | $2K | |
| 0270 | <1% | 162 | $2K | |
| 88108 | <1% | 29 | $2K | |
| 0637 | <1% | 175 | $2K | |
| 85651 | <1% | 320 | $2K | |
| 83550 | <1% | 346 | $1K | |
| 80061 | Lipid panel | <1% | 214 | $1K |
| 52000 | <1% | 20 | $1K | |
| 96409 | <1% | 43 | $1K | |
| 96401 | <1% | 68 | $1K | |
| 87077 | <1% | 131 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 51 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 73 | $1K |
| 85045 | <1% | 192 | $1K | |
| Z7610 | <1% | 83 | $1K | |
| 76641 | <1% | 12 | $849.36 | |
| 87799 | <1% | 15 | $728.10 | |
| 51798 | <1% | 38 | $649.84 | |
| J2704 | Injection, propofol, 10 mg | <1% | 68 | $629.97 |
| 84403 | <1% | 90 | $578.88 | |
| 87186 | <1% | 41 | $491.85 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 86 | $461.85 |
| 90713 | <1% | 12 | $406.00 | |
| 84152 | <1% | 33 | $387.98 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16 | $385.65 |
| 90715 | <1% | 12 | $385.20 | |
| 82607 | <1% | 50 | $380.48 | |
| 82746 | <1% | 26 | $272.69 | |
| 86140 | <1% | 142 | $271.72 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15 | $244.83 |
| 90648 | <1% | 12 | $208.40 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 16 | $200.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27 | $108.12 |
| 82668 | <1% | 13 | $104.32 | |
| 86803 | <1% | 13 | $80.09 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 14 | $60.26 |
| 82570 | <1% | 46 | $38.67 | |
| 84156 | <1% | 14 | $2.58 | |
| 0300 | 0% | 66 | $0.00 | |
| 0636 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKIEWICZ, THOMAS (SVP & CEO, KECK MEDICINE OF USC)
Parent organizationUNICERSITY OF SOUTHERN CALIFOR
| Provider | Location | Paid |
|---|---|---|
| University of Southern California | Los Angeles, CA | $19.48M |
| University of Southern California | Glendale, CA | $8.63M |
| University of Southern California | Alhambra, CA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.